Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

▤ Summary

Inhibrx says the FDA accepted its BLA for ozekibart in unresectable or metastatic conventional chondrosarcoma. The agency found no filing review issues and set a PDUFA goal date of April 14, 2027. The company positions ozekibart as a potential first approved treatment for this rare cancer and points to positive results from its registrational ChonDRAgon study. This matters commercially because a possible approval would move Inhibrx into launch planning, manufacturing, commercialization, and market access work.

▦ Linked Companies